Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.

ABSTRACT: In patients with metastatic castrate-resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development of non-invasive biomarkers informative of treatment response with novel agents targeting the androgen-receptor (AR) pathway, such as abiraterone or enzalutamide. However, the relationship between ctDNA abundance, detectable somatic genomic alterations and clinical progression of mCRPC remains unexplored. Our study aimed to investigate changes in plasma DNA during disease progression and their associations with clinical variables in mCRPC patients. We analyzed ctDNA in two cohorts including 94 plasma samples from 25 treatment courses (23 patients) and 334 plasma samples from 125 patients, respectively. We conducted whole-genome sequenc

SUBMITTER: Belic J 

PROVIDER: S-EPMC6099279 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature